Clearside Biomedical (CLSD) Competitors $3.79 +0.09 (+2.43%) Closing price 10/17/2025 03:50 PM EasternExtended Trading$3.72 -0.07 (-1.85%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. KLRS, IMMX, IZTC, ASRT, EQ, UNCY, VXRT, XBIT, RPTX, and COEPShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), Assertio (ASRT), Equillium (EQ), Unicycive Therapeutics (UNCY), Vaxart (VXRT), XBiotech (XBIT), Repare Therapeutics (RPTX), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Its Competitors Kalaris Therapeutics Immix Biopharma Invizyne Technologies Assertio Equillium Unicycive Therapeutics Vaxart XBiotech Repare Therapeutics Coeptis Therapeutics Kalaris Therapeutics (NASDAQ:KLRS) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Do analysts prefer KLRS or CLSD? Kalaris Therapeutics presently has a consensus price target of $3.00, suggesting a potential downside of 35.21%. Clearside Biomedical has a consensus price target of $63.00, suggesting a potential upside of 1,562.27%. Given Clearside Biomedical's higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Do institutionals and insiders have more ownership in KLRS or CLSD? 66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are owned by institutional investors. 75.0% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 6.7% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, KLRS or CLSD? Kalaris Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Which has better valuation & earnings, KLRS or CLSD? Clearside Biomedical has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/AClearside Biomedical$1.66M11.96-$34.35M-$5.55-0.68 Does the media favor KLRS or CLSD? In the previous week, Kalaris Therapeutics had 1 more articles in the media than Clearside Biomedical. MarketBeat recorded 1 mentions for Kalaris Therapeutics and 0 mentions for Clearside Biomedical. Kalaris Therapeutics' average media sentiment score of 0.67 beat Clearside Biomedical's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kalaris Therapeutics Positive Clearside Biomedical Neutral Is KLRS or CLSD more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to Clearside Biomedical's net margin of -665.19%. Clearside Biomedical's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -81.02% -65.15% Clearside Biomedical -665.19%N/A -124.15% SummaryKalaris Therapeutics beats Clearside Biomedical on 8 of the 14 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.86M$3.44B$6.13B$10.55BDividend YieldN/A2.27%5.72%4.83%P/E Ratio-0.6823.3151.2627.06Price / Sales11.96487.09602.44132.30Price / CashN/A45.2825.8230.35Price / Book-0.4910.3812.246.58Net Income-$34.35M-$52.81M$3.33B$276.84M7 Day Performance-4.29%2.08%0.62%-0.72%1 Month Performance0.80%12.60%6.83%2.16%1 Year Performance-78.03%11.18%59.07%34.63% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical1.4511 of 5 stars$3.79+2.4%$63.00+1,562.3%-78.0%$19.86M$1.66M-0.6830Positive NewsKLRSKalaris Therapeutics1.379 of 5 stars$4.76+7.0%$3.00-37.0%N/A$83.23MN/A0.00110IMMXImmix Biopharma3.3417 of 5 stars$2.50flat$8.00+220.0%+66.9%$82.59MN/A-3.259Positive NewsIZTCInvizyne TechnologiesN/A$12.95-4.1%N/AN/A$80.96MN/A0.0029Gap DownASRTAssertio2.708 of 5 stars$0.84+0.9%$2.38+182.0%-31.0%$80.36M$124.96M-1.8720Positive NewsEQEquillium0.451 of 5 stars$1.28-4.5%$1.00-21.9%+29.2%$79.73M$41.10M-2.2940Negative NewsShort Interest ↑UNCYUnicycive Therapeutics2.6506 of 5 stars$4.49+1.1%$57.00+1,169.5%+9.8%$78.42M$680K-1.099VXRTVaxart1.5694 of 5 stars$0.34-2.4%$2.00+489.6%-56.1%$77.66M$47.40M-1.26120Gap UpXBITXBiotech1.879 of 5 stars$2.56+0.8%N/A-67.0%$77.44M$4.01M-2.78100Positive NewsShort Interest ↓RPTXRepare Therapeutics2.7409 of 5 stars$1.82+1.1%$4.50+147.3%-46.6%$77.33M$53.48M-0.71180COEPCoeptis Therapeutics0.7014 of 5 stars$15.55-1.0%N/A+267.2%$75.68MN/A-2.682Short Interest ↑ Related Companies and Tools Related Companies Kalaris Therapeutics Competitors Immix Biopharma Competitors Invizyne Technologies Competitors Assertio Competitors Equillium Competitors Unicycive Therapeutics Competitors Vaxart Competitors XBiotech Competitors Repare Therapeutics Competitors Coeptis Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
